The viokace market research report is one of a series of new reports that provides viokace market statistics, including the viokace industry global market size, regional shares, competitors with the viokace market share, detailed viokace market segments, market trends, and opportunities, and any further data you may need to thrive in the viokace industry. This viokace market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to rising diabetes, increasing investment in research and development, increasing clinical trials, increasing personalized medicine, and increasing government initiatives. Major trends in the forecast period include technological advancement, strategic collaboration, facility expansion, focus on product launch, and investment in research and development.
The increasing prevalence of pancreatic disorders is expected to significantly contribute to the growth of the Viokace market in the future. Pancreatic disorders encompass a range of conditions that affect the pancreas, an organ responsible for producing digestive enzymes and hormones such as insulin. The rise in pancreatic disorders can be attributed to factors such as an aging population, unhealthy lifestyle habits, higher rates of obesity, and the increasing prevalence of diseases such as diabetes, which can impair pancreatic function. Viokace aids in managing these disorders by providing digestive enzymes that help break down fats, proteins, and carbohydrates, crucial for individuals with conditions such as chronic pancreatitis or cystic fibrosis, where the pancreas does not produce enough enzymes for proper digestion and nutrient absorption. For example, in February 2023, Cancer Research UK projected that the incidence of pancreatic cancer in the UK is expected to rise by 5% between 2023-2025 and 2038-2040, with the rate reaching an average of 19 cases per 100,000 people annually by 2038-2040. This rising prevalence of pancreatic disorders is expected to drive the demand for Viokace.
The growth of the geriatric population is anticipated to further propel the expansion of the Viokace market. This demographic typically includes individuals aged 65 and older, who often face unique health challenges due to aging. The increase in the geriatric population is largely attributed to advancements in healthcare, which have led to longer life expectancy and declining birth rates. Viokace supports older adults by providing essential pancreatic enzymes that improve digestion and nutrient absorption, particularly for those who may experience pancreatic insufficiency due to age-related conditions such as chronic pancreatitis or other pancreatic disorders. This helps enhance their overall digestive health and quality of life. According to the Administration for Community Living, in May 2024, 17.3% of the U.S. population was aged 65 or older, with projections indicating this proportion will increase to 22% by 2040. As such, the growing geriatric population is expected to drive the growth of the Viokace market.
Rising healthcare expenditure is also likely to support the growth of the Viokace market. Healthcare expenditure refers to the financial resources allocated by governments, private insurers, and individuals toward healthcare services, including medical treatments, infrastructure, equipment, and personnel. Factors such as an aging population, the increasing prevalence of chronic diseases, advancements in medical technology, and the growing demand for better healthcare services are all contributing to higher healthcare spending. This increased expenditure improves access to treatments such as Viokace by making them more affordable and available through enhanced healthcare infrastructure and better reimbursement policies. For example, the Office for National Statistics reported in May 2024 that total healthcare expenditure in the UK increased by 5.6% in nominal terms from 2022 to 2023, a significant rise compared to the 0.9% growth observed the previous year. This growing healthcare expenditure is expected to fuel the demand for Viokace.
The key company operating in the viokace market is AbbVie Inc.
North America was the largest region in the viokace market in 2024. The regions covered in viokace report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the viokace market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Viokace is a prescription medication containing pancrelipase, an enzyme replacement therapy used to treat exocrine pancreatic insufficiency (EPI) in individuals with conditions such as chronic pancreatitis or cystic fibrosis. It aids digestion by supplementing the body's natural pancreatic enzymes, improving nutrient absorption, and alleviating symptoms such as malabsorption and weight loss.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Viokace include exocrine pancreatic insufficiency, chronic pancreatitis, and other pancreatic disorders. Exocrine pancreatic insufficiency (EPI) occurs when the pancreas does not produce enough digestive enzymes, making it difficult to digest food and absorb nutrients. Viokace is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a broad range of patients, including adults and the elderly.
The viokace market consists of sales of pharmaceutical products, diagnostic reagents, and medical devices. This market also encompasses associated costs for distribution, healthcare professional services, and patient support programs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising diabetes, increasing investment in research and development, increasing clinical trials, increasing personalized medicine, and increasing government initiatives. Major trends in the forecast period include technological advancement, strategic collaboration, facility expansion, focus on product launch, and investment in research and development.
The increasing prevalence of pancreatic disorders is expected to significantly contribute to the growth of the Viokace market in the future. Pancreatic disorders encompass a range of conditions that affect the pancreas, an organ responsible for producing digestive enzymes and hormones such as insulin. The rise in pancreatic disorders can be attributed to factors such as an aging population, unhealthy lifestyle habits, higher rates of obesity, and the increasing prevalence of diseases such as diabetes, which can impair pancreatic function. Viokace aids in managing these disorders by providing digestive enzymes that help break down fats, proteins, and carbohydrates, crucial for individuals with conditions such as chronic pancreatitis or cystic fibrosis, where the pancreas does not produce enough enzymes for proper digestion and nutrient absorption. For example, in February 2023, Cancer Research UK projected that the incidence of pancreatic cancer in the UK is expected to rise by 5% between 2023-2025 and 2038-2040, with the rate reaching an average of 19 cases per 100,000 people annually by 2038-2040. This rising prevalence of pancreatic disorders is expected to drive the demand for Viokace.
The growth of the geriatric population is anticipated to further propel the expansion of the Viokace market. This demographic typically includes individuals aged 65 and older, who often face unique health challenges due to aging. The increase in the geriatric population is largely attributed to advancements in healthcare, which have led to longer life expectancy and declining birth rates. Viokace supports older adults by providing essential pancreatic enzymes that improve digestion and nutrient absorption, particularly for those who may experience pancreatic insufficiency due to age-related conditions such as chronic pancreatitis or other pancreatic disorders. This helps enhance their overall digestive health and quality of life. According to the Administration for Community Living, in May 2024, 17.3% of the U.S. population was aged 65 or older, with projections indicating this proportion will increase to 22% by 2040. As such, the growing geriatric population is expected to drive the growth of the Viokace market.
Rising healthcare expenditure is also likely to support the growth of the Viokace market. Healthcare expenditure refers to the financial resources allocated by governments, private insurers, and individuals toward healthcare services, including medical treatments, infrastructure, equipment, and personnel. Factors such as an aging population, the increasing prevalence of chronic diseases, advancements in medical technology, and the growing demand for better healthcare services are all contributing to higher healthcare spending. This increased expenditure improves access to treatments such as Viokace by making them more affordable and available through enhanced healthcare infrastructure and better reimbursement policies. For example, the Office for National Statistics reported in May 2024 that total healthcare expenditure in the UK increased by 5.6% in nominal terms from 2022 to 2023, a significant rise compared to the 0.9% growth observed the previous year. This growing healthcare expenditure is expected to fuel the demand for Viokace.
The key company operating in the viokace market is AbbVie Inc.
North America was the largest region in the viokace market in 2024. The regions covered in viokace report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the viokace market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Viokace is a prescription medication containing pancrelipase, an enzyme replacement therapy used to treat exocrine pancreatic insufficiency (EPI) in individuals with conditions such as chronic pancreatitis or cystic fibrosis. It aids digestion by supplementing the body's natural pancreatic enzymes, improving nutrient absorption, and alleviating symptoms such as malabsorption and weight loss.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Viokace include exocrine pancreatic insufficiency, chronic pancreatitis, and other pancreatic disorders. Exocrine pancreatic insufficiency (EPI) occurs when the pancreas does not produce enough digestive enzymes, making it difficult to digest food and absorb nutrients. Viokace is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a broad range of patients, including adults and the elderly.
The viokace market consists of sales of pharmaceutical products, diagnostic reagents, and medical devices. This market also encompasses associated costs for distribution, healthcare professional services, and patient support programs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Viokace Market Characteristics4. Viokace Market Trends And Strategies5. Viokace Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Viokace Pricing Analysis & Forecasts30. Global Viokace Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Viokace Market32. Recent Developments In The Viokace Market
3. Viokace Market Biologic Drug Characteristics
6. Global Viokace Growth Analysis And Strategic Analysis Framework
8. Viokace Market Segmentation
9. Global Viokace Epidemiology Of Clinical Indications
10. Viokace Market Regional And Country Analysis
11. Asia-Pacific Viokace Market
12. China Viokace Market
13. India Viokace Market
14. Japan Viokace Market
15. Australia Viokace Market
16. South Korea Viokace Market
17. Western Europe Viokace Market
18. UK Viokace Market
19. Germany Viokace Market
20. France Viokace Market
21. Eastern Europe Viokace Market
22. North America Viokace Market
23. USA Viokace Market
24. Canada Viokace Market
25. South America Viokace Market
26. Middle East Viokace Market
27. Africa Viokace Market
28. Viokace Market Competitive Landscape And Company Profiles
29. Global Viokace Market Pipeline Analysis
33. Viokace Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Viokace Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on viokace market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for viokace ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viokace market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Exocrine Pancreatic Insufficiency; Chronic Pancreatitis; Other Pancreatic Disorders2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult; Geriatric
Key Companies Profiled: AbbVie Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- AbbVie Inc.
